[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fUS2j2_Vi9myGXGRJNJ7UNi5dkL4loyizOEhbng_OZog":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":35,"phaseBuckets":71,"rows":78},"Lund University",[4,6],"Lund University Hospital",292,false,54,14,186230,13,235,[15,18,20,22,25,28,30,32],{"name":16,"count":17},"Obesity",10,{"name":19,"count":17},"Healthy",{"name":21,"count":17},"Type 2 Diabetes",{"name":23,"count":24},"Metabolic Syndrome",8,{"name":26,"count":27},"Breast Cancer",5,{"name":29,"count":27},"Celiac Disease in Children",{"name":31,"count":27},"Healthy Subjects",{"name":33,"count":34},"Anxiety",4,[36,41,46,51,56,61,66],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03425669","Acoustic and Vestibular Noise as Possible Non-pharmacological Treatment of ADHD in School Children","2024-05-31","Active medication",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05387603","Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","2026-10-01","177Lu-DOTATOC",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT03773367","Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma.","2026-11-30","Fluorouracil",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03131726","Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)","2027-01-26","Simvastatin 40mg",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05224401","Pivmecillinam With Amoxicillin\u002FClavulanic Acid for Step Down Oral Therapy in ESBL UTIs","2027-09-01","Pivmecillinam and amoxicillin\u002Fclavulanic acid",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06389799","A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)","2027-12-31","Pemigatinib",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT04335669","NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","2035-09","epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab",[72,73,74,75,76,77],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[79,104,122,145,163,187,205,229,252,270,288,311,329,351,408,426,451,475,501,528,546,568,596,614,638,663,703,741,767,785,803,833,851,875,893,911,929,983,1010,1035,1059,1085,1103,1121,1145,1172,1190,1214,1238,1261,1291,1309,1327,1345,1363,1381,1399,1417,1435,1453,1471,1489,1507,1525,1543,1561,1579,1620,1654,1682,1700,1718,1736,1754,1778,1804,1827,1852,1879,1897,1923,1947,1965,1989,2014,2032,2050,2075,2102],{"intervention":70,"totalTrials":80,"cells":81},1,{"EARLY_PHASE1":82,"PHASE1":85,"PHASE2":87,"PHASE3":89,"PHASE4":100,"NA":102},{"trials":83,"activeCount":84},[],0,{"trials":86,"activeCount":84},[],{"trials":88,"activeCount":84},[],{"trials":90,"activeCount":80,"soonestReadout":69},[91],{"nctId":67,"briefTitle":68,"status":92,"phases":93,"primaryCompletion":69,"completion":69,"start":94,"enrollment":95,"conditions":96,"interventions":98},"ACTIVE_NOT_RECRUITING",[75],"2019-12-20",325,[26,97],"Triple Negative Breast Neoplasms",[70,99],"epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab",{"trials":101,"activeCount":84},[],{"trials":103,"activeCount":84},[],{"intervention":99,"totalTrials":80,"cells":105},{"EARLY_PHASE1":106,"PHASE1":108,"PHASE2":110,"PHASE3":112,"PHASE4":118,"NA":120},{"trials":107,"activeCount":84},[],{"trials":109,"activeCount":84},[],{"trials":111,"activeCount":84},[],{"trials":113,"activeCount":80,"soonestReadout":69},[114],{"nctId":67,"briefTitle":68,"status":92,"phases":115,"primaryCompletion":69,"completion":69,"start":94,"enrollment":95,"conditions":116,"interventions":117},[75],[26,97],[70,99],{"trials":119,"activeCount":84},[],{"trials":121,"activeCount":84},[],{"intervention":45,"totalTrials":80,"cells":123},{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":141,"NA":143},{"trials":125,"activeCount":84},[],{"trials":127,"activeCount":84},[],{"trials":129,"activeCount":84},[],{"trials":131,"activeCount":80,"soonestReadout":44},[132],{"nctId":42,"briefTitle":43,"status":133,"phases":134,"primaryCompletion":44,"completion":44,"start":135,"enrollment":136,"conditions":137,"interventions":139},"RECRUITING",[75],"2022-11-01",300,[138],"Neuroendocrine Tumors",[45,140],"Capecitabine",{"trials":142,"activeCount":84},[],{"trials":144,"activeCount":84},[],{"intervention":140,"totalTrials":80,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":159,"NA":161},{"trials":148,"activeCount":84},[],{"trials":150,"activeCount":84},[],{"trials":152,"activeCount":84},[],{"trials":154,"activeCount":80,"soonestReadout":44},[155],{"nctId":42,"briefTitle":43,"status":133,"phases":156,"primaryCompletion":44,"completion":44,"start":135,"enrollment":136,"conditions":157,"interventions":158},[75],[138],[45,140],{"trials":160,"activeCount":84},[],{"trials":162,"activeCount":84},[],{"intervention":60,"totalTrials":80,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":183,"NA":185},{"trials":166,"activeCount":84},[],{"trials":168,"activeCount":84},[],{"trials":170,"activeCount":84},[],{"trials":172,"activeCount":80,"soonestReadout":59},[173],{"nctId":57,"briefTitle":58,"status":133,"phases":174,"primaryCompletion":59,"completion":59,"start":175,"enrollment":176,"conditions":177,"interventions":181},[75],"2023-05-29",330,[178,179,180],"Urinary Tract Infections","Bacteremia","Antibiotic Resistant Infection",[60,182],"Standard treatment, ciprofloxacin, trimethoprim\u002Fsulfamethoxazole or ertapenem depending on susceptibility",{"trials":184,"activeCount":84},[],{"trials":186,"activeCount":84},[],{"intervention":182,"totalTrials":80,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":201,"NA":203},{"trials":190,"activeCount":84},[],{"trials":192,"activeCount":84},[],{"trials":194,"activeCount":84},[],{"trials":196,"activeCount":80,"soonestReadout":59},[197],{"nctId":57,"briefTitle":58,"status":133,"phases":198,"primaryCompletion":59,"completion":59,"start":175,"enrollment":176,"conditions":199,"interventions":200},[75],[178,179,180],[60,182],{"trials":202,"activeCount":84},[],{"trials":204,"activeCount":84},[],{"intervention":55,"totalTrials":80,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":213,"PHASE4":225,"NA":227},{"trials":208,"activeCount":84},[],{"trials":210,"activeCount":84},[],{"trials":212,"activeCount":84},[],{"trials":214,"activeCount":80,"soonestReadout":54},[215],{"nctId":52,"briefTitle":53,"status":133,"phases":216,"primaryCompletion":54,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":224},[75],"2028-03-30","2018-01-26",80,[221,222,223],"Graves Ophthalmopathy","Thyroid Associated Ophthalmopathy","Thyroid Associated Orbitopathy",[55],{"trials":226,"activeCount":84},[],{"trials":228,"activeCount":84},[],{"intervention":50,"totalTrials":80,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":246,"PHASE4":248,"NA":250},{"trials":232,"activeCount":84},[],{"trials":234,"activeCount":84},[],{"trials":236,"activeCount":80,"soonestReadout":49},[237],{"nctId":47,"briefTitle":48,"status":92,"phases":238,"primaryCompletion":49,"completion":49,"start":239,"enrollment":240,"conditions":241,"interventions":243},[74],"2018-12-14",60,[242],"Resectable Gastric and Gastroesophageal Junction Adenocarcinoma",[50,244,245],"Oxaliplatin","Irinotecan",{"trials":247,"activeCount":84},[],{"trials":249,"activeCount":84},[],{"trials":251,"activeCount":84},[],{"intervention":244,"totalTrials":80,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":264,"PHASE4":266,"NA":268},{"trials":255,"activeCount":84},[],{"trials":257,"activeCount":84},[],{"trials":259,"activeCount":80,"soonestReadout":49},[260],{"nctId":47,"briefTitle":48,"status":92,"phases":261,"primaryCompletion":49,"completion":49,"start":239,"enrollment":240,"conditions":262,"interventions":263},[74],[242],[50,244,245],{"trials":265,"activeCount":84},[],{"trials":267,"activeCount":84},[],{"trials":269,"activeCount":84},[],{"intervention":245,"totalTrials":80,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":282,"PHASE4":284,"NA":286},{"trials":273,"activeCount":84},[],{"trials":275,"activeCount":84},[],{"trials":277,"activeCount":80,"soonestReadout":49},[278],{"nctId":47,"briefTitle":48,"status":92,"phases":279,"primaryCompletion":49,"completion":49,"start":239,"enrollment":240,"conditions":280,"interventions":281},[74],[242],[50,244,245],{"trials":283,"activeCount":84},[],{"trials":285,"activeCount":84},[],{"trials":287,"activeCount":84},[],{"intervention":65,"totalTrials":80,"cells":289},{"EARLY_PHASE1":290,"PHASE1":292,"PHASE2":294,"PHASE3":305,"PHASE4":307,"NA":309},{"trials":291,"activeCount":84},[],{"trials":293,"activeCount":84},[],{"trials":295,"activeCount":80,"soonestReadout":64},[296],{"nctId":62,"briefTitle":63,"status":133,"phases":297,"primaryCompletion":64,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":303},[74],"2028-12-31","2024-06-20",33,[302],"Dedifferentiated Liposarcoma",[65,304],"Retifanlimab",{"trials":306,"activeCount":84},[],{"trials":308,"activeCount":84},[],{"trials":310,"activeCount":84},[],{"intervention":304,"totalTrials":80,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":323,"PHASE4":325,"NA":327},{"trials":314,"activeCount":84},[],{"trials":316,"activeCount":84},[],{"trials":318,"activeCount":80,"soonestReadout":64},[319],{"nctId":62,"briefTitle":63,"status":133,"phases":320,"primaryCompletion":64,"completion":298,"start":299,"enrollment":300,"conditions":321,"interventions":322},[74],[302],[65,304],{"trials":324,"activeCount":84},[],{"trials":326,"activeCount":84},[],{"trials":328,"activeCount":84},[],{"intervention":40,"totalTrials":80,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":341},{"trials":332,"activeCount":84},[],{"trials":334,"activeCount":84},[],{"trials":336,"activeCount":84},[],{"trials":338,"activeCount":84},[],{"trials":340,"activeCount":84},[],{"trials":342,"activeCount":80,"soonestReadout":39},[343],{"nctId":37,"briefTitle":38,"status":133,"phases":344,"primaryCompletion":39,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":350},[77],"2027-05-31","2019-05-01",70,[349],"ADHD",[40],{"intervention":352,"totalTrials":34,"cells":353},"Vildagliptin",{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":406},{"trials":355,"activeCount":84},[],{"trials":357,"activeCount":84},[],{"trials":359,"activeCount":84},[],{"trials":361,"activeCount":84},[],{"trials":363,"activeCount":84},[364,375,386,397],{"nctId":365,"briefTitle":366,"status":367,"phases":368,"primaryCompletion":369,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":373},"NCT02475070","Vildagliptin Versus Dapagliflozin on Glucagon","COMPLETED",[76],"2017-06","2016-01",28,[21],[352,374],"Dapagliflozin",{"nctId":376,"briefTitle":377,"status":367,"phases":378,"primaryCompletion":379,"completion":380,"start":381,"enrollment":371,"conditions":382,"interventions":385},"NCT01147276","Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes",[76],"2011-09","2011-12","2010-09",[383,384],"Diabetes","Hypoglycemia",[352],{"nctId":387,"briefTitle":388,"status":367,"phases":389,"primaryCompletion":369,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":394},"NCT02089438","DPP-4 Inhibition, Incretins and Islet Function",[76],"2017-08","2014-05",24,[21],[395,352,396],"Saxagliptin","Sitagliptin",{"nctId":398,"briefTitle":399,"status":367,"phases":400,"primaryCompletion":401,"completion":402,"start":403,"enrollment":371,"conditions":404,"interventions":405},"NCT01219400","Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes",[76],"2013-10","2013-12","2012-01",[383],[352],{"trials":407,"activeCount":84},[],{"intervention":374,"totalTrials":80,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":424},{"trials":411,"activeCount":84},[],{"trials":413,"activeCount":84},[],{"trials":415,"activeCount":84},[],{"trials":417,"activeCount":84},[],{"trials":419,"activeCount":84},[420],{"nctId":365,"briefTitle":366,"status":367,"phases":421,"primaryCompletion":369,"completion":369,"start":370,"enrollment":371,"conditions":422,"interventions":423},[76],[21],[352,374],{"trials":425,"activeCount":84},[],{"intervention":427,"totalTrials":80,"cells":428},"Fentanyl (5 microgram\u002Fml) prediluted ampoules",{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":435,"PHASE4":437,"NA":449},{"trials":430,"activeCount":84},[],{"trials":432,"activeCount":84},[],{"trials":434,"activeCount":84},[],{"trials":436,"activeCount":84},[],{"trials":438,"activeCount":84},[439],{"nctId":440,"briefTitle":441,"status":367,"phases":442,"primaryCompletion":443,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":448},"NCT03897452","NeoFent-I Study; Fentanyl Treatment in Newborn Infants; a Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study",[76],"2014-12-31","2012-11",32,[447],"Pain",[427],{"trials":450,"activeCount":84},[],{"intervention":452,"totalTrials":80,"cells":453},"Oktokog alpha",{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":462,"NA":473},{"trials":455,"activeCount":84},[],{"trials":457,"activeCount":84},[],{"trials":459,"activeCount":84},[],{"trials":461,"activeCount":84},[],{"trials":463,"activeCount":84},[464],{"nctId":465,"briefTitle":466,"status":367,"phases":467,"primaryCompletion":468,"completion":468,"start":469,"enrollment":10,"conditions":470,"interventions":472},"NCT03915080","Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A",[76],"2021-04-09","2016-12",[471],"Hemophilia A",[452],{"trials":474,"activeCount":84},[],{"intervention":476,"totalTrials":80,"cells":477},"Gentamicins",{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":484,"PHASE4":486,"NA":499},{"trials":479,"activeCount":84},[],{"trials":481,"activeCount":84},[],{"trials":483,"activeCount":84},[],{"trials":485,"activeCount":84},[],{"trials":487,"activeCount":84},[488],{"nctId":489,"briefTitle":490,"status":491,"phases":492,"primaryCompletion":493,"completion":494,"start":495,"enrollment":84,"conditions":496,"interventions":498},"NCT02379754","Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function","WITHDRAWN",[76],"2019-06","2020-09","2015-01",[497],"Vestibular Schwannoma",[476],{"trials":500,"activeCount":84},[],{"intervention":502,"totalTrials":80,"cells":503},"Insulin",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":510,"PHASE4":512,"NA":526},{"trials":505,"activeCount":84},[],{"trials":507,"activeCount":84},[],{"trials":509,"activeCount":84},[],{"trials":511,"activeCount":84},[],{"trials":513,"activeCount":84},[514],{"nctId":515,"briefTitle":516,"status":367,"phases":517,"primaryCompletion":518,"completion":519,"start":520,"enrollment":521,"conditions":522,"interventions":525},"NCT01109927","Early Insulin Treatment in Patients With Latent Autoimmune Diabetes",[76],"2002-04","2005-05","1995-02",42,[523,524],"Diabetes, Autoimmune","Diabetes Mellitus, Adult-Onset",[502],{"trials":527,"activeCount":84},[],{"intervention":395,"totalTrials":80,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":538,"NA":544},{"trials":531,"activeCount":84},[],{"trials":533,"activeCount":84},[],{"trials":535,"activeCount":84},[],{"trials":537,"activeCount":84},[],{"trials":539,"activeCount":84},[540],{"nctId":387,"briefTitle":388,"status":367,"phases":541,"primaryCompletion":369,"completion":390,"start":391,"enrollment":392,"conditions":542,"interventions":543},[76],[21],[395,352,396],{"trials":545,"activeCount":84},[],{"intervention":547,"totalTrials":80,"cells":548},"Gentamicin",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":557,"NA":566},{"trials":550,"activeCount":84},[],{"trials":552,"activeCount":84},[],{"trials":554,"activeCount":84},[],{"trials":556,"activeCount":84},[],{"trials":558,"activeCount":84},[559],{"nctId":560,"briefTitle":561,"status":491,"phases":562,"primaryCompletion":494,"completion":494,"start":563,"enrollment":84,"conditions":564,"interventions":565},"NCT02415257","Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function",[76],"2015-04",[497],[547],{"trials":567,"activeCount":84},[],{"intervention":569,"totalTrials":80,"cells":570},"Betamethasone",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":579,"NA":594},{"trials":572,"activeCount":84},[],{"trials":574,"activeCount":84},[],{"trials":576,"activeCount":84},[],{"trials":578,"activeCount":84},[],{"trials":580,"activeCount":84},[581],{"nctId":582,"briefTitle":583,"status":584,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":592},"NCT02912182","Acute Unilateral Vestibulopathy and Corticosteroid Treatment","TERMINATED",[76],"2021-03-01","2015-12",78,[590,591],"Vestibular Diseases","Vestibular Neuronitis",[569,593],"Prednisolone",{"trials":595,"activeCount":84},[],{"intervention":593,"totalTrials":80,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":606,"NA":612},{"trials":599,"activeCount":84},[],{"trials":601,"activeCount":84},[],{"trials":603,"activeCount":84},[],{"trials":605,"activeCount":84},[],{"trials":607,"activeCount":84},[608],{"nctId":582,"briefTitle":583,"status":584,"phases":609,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":610,"interventions":611},[76],[590,591],[569,593],{"trials":613,"activeCount":84},[],{"intervention":615,"totalTrials":80,"cells":616},"Lixisenatide",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":636},{"trials":618,"activeCount":84},[],{"trials":620,"activeCount":84},[],{"trials":622,"activeCount":84},[],{"trials":624,"activeCount":84},[],{"trials":626,"activeCount":84},[627],{"nctId":628,"briefTitle":629,"status":367,"phases":630,"primaryCompletion":631,"completion":632,"start":402,"enrollment":633,"conditions":634,"interventions":635},"NCT02020629","Study on Lixisenatide and Counterregulation to Hypoglycemia",[76],"2014-08","2015-08",18,[21],[615],{"trials":637,"activeCount":84},[],{"intervention":639,"totalTrials":80,"cells":640},"Chlorhexidine Topical",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":647,"PHASE4":649,"NA":661},{"trials":642,"activeCount":84},[],{"trials":644,"activeCount":84},[],{"trials":646,"activeCount":84},[],{"trials":648,"activeCount":84},[],{"trials":650,"activeCount":84},[651],{"nctId":652,"briefTitle":653,"status":367,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":660},"NCT03940729","PWID; Longitudinal S Aureus Colonization Pattern and the Impact on Infection Frequency by Regular Showers With Chlorhexidine",[76],"2020-01-01","2016-12-15",61,[659],"Intravenous Drug Abuse, S Aureus Colonization",[639],{"trials":662,"activeCount":84},[],{"intervention":664,"totalTrials":665,"cells":666},"cetuximab",2,{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":684,"PHASE3":686,"PHASE4":699,"NA":701},{"trials":668,"activeCount":84},[],{"trials":670,"activeCount":84},[671],{"nctId":672,"briefTitle":673,"status":367,"phases":674,"primaryCompletion":675,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":680},"NCT01621217","Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0",[73],"2020-01","2012-06",21,[679],"Locally Advanced Cancer in the Anal Region",[681,682,683],"Cetuximab","Mitomycin C","5-Fluoruracil",{"trials":685,"activeCount":84},[],{"trials":687,"activeCount":84},[688],{"nctId":689,"briefTitle":690,"status":367,"phases":691,"primaryCompletion":692,"completion":692,"start":693,"enrollment":694,"conditions":695,"interventions":697},"NCT01969877","A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.",[75],"2018-04","2013-11",298,[696],"Locally Advanced Head and Neck Cancer",[664,698],"cisplatin",{"trials":700,"activeCount":84},[],{"trials":702,"activeCount":84},[],{"intervention":704,"totalTrials":665,"cells":705},"bevacizumab",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":737,"NA":739},{"trials":707,"activeCount":84},[],{"trials":709,"activeCount":84},[],{"trials":711,"activeCount":84},[],{"trials":713,"activeCount":84},[714,725],{"nctId":715,"briefTitle":716,"status":367,"phases":717,"primaryCompletion":402,"completion":402,"start":718,"enrollment":719,"conditions":720,"interventions":722},"NCT01229813","Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.",[75],"2010-10",233,[721],"Colorectal Cancer",[723,704,704,724],"bevacizumab, erlotinib","low dose capecitabine",{"nctId":726,"briefTitle":727,"status":367,"phases":728,"primaryCompletion":729,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":735},"NCT00598156","Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +\u002F- Tarceva",[75],"2009-10","2012-08","2007-06",249,[734],"Metastatic Colorectal Cancer",[736,704],"erlotinib",{"trials":738,"activeCount":84},[],{"trials":740,"activeCount":84},[],{"intervention":742,"totalTrials":80,"cells":743},"cisplatinum or carboplatin and e.g.etoposide.",{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":748,"PHASE3":750,"PHASE4":763,"NA":765},{"trials":745,"activeCount":84},[],{"trials":747,"activeCount":84},[],{"trials":749,"activeCount":84},[],{"trials":751,"activeCount":84},[752],{"nctId":753,"briefTitle":754,"status":367,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":761},"NCT00717938","A Study of Standard Treatment +\u002F- Enoxaparin in Small Cell Lung Cancer",[75],"2017-05","2008-06",390,[760],"Small Cell Lung Cancer",[742,762],"cisplatinum or carboplatin and e.g.etoposide+enoxaparin",{"trials":764,"activeCount":84},[],{"trials":766,"activeCount":84},[],{"intervention":762,"totalTrials":80,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":781,"NA":783},{"trials":770,"activeCount":84},[],{"trials":772,"activeCount":84},[],{"trials":774,"activeCount":84},[],{"trials":776,"activeCount":84},[777],{"nctId":753,"briefTitle":754,"status":367,"phases":778,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":779,"interventions":780},[75],[760],[742,762],{"trials":782,"activeCount":84},[],{"trials":784,"activeCount":84},[],{"intervention":698,"totalTrials":80,"cells":786},{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":791,"PHASE3":793,"PHASE4":799,"NA":801},{"trials":788,"activeCount":84},[],{"trials":790,"activeCount":84},[],{"trials":792,"activeCount":84},[],{"trials":794,"activeCount":84},[795],{"nctId":689,"briefTitle":690,"status":367,"phases":796,"primaryCompletion":692,"completion":692,"start":693,"enrollment":694,"conditions":797,"interventions":798},[75],[696],[664,698],{"trials":800,"activeCount":84},[],{"trials":802,"activeCount":84},[],{"intervention":804,"totalTrials":80,"cells":805},"Lidocaine",{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":812,"PHASE4":829,"NA":831},{"trials":807,"activeCount":84},[],{"trials":809,"activeCount":84},[],{"trials":811,"activeCount":84},[],{"trials":813,"activeCount":84},[814],{"nctId":815,"briefTitle":816,"status":367,"phases":817,"primaryCompletion":818,"completion":819,"start":820,"enrollment":821,"conditions":822,"interventions":827},"NCT05153785","Perioperative Intravenous Lidocaine in Liver Surgery",[74,75],"2025-06-12","2025-12-06","2021-11-15",124,[823,824,825,826],"Liver Metastases","Liver Cancer","Postoperative Pain","Opioid Use",[804,828],"Normal saline",{"trials":830,"activeCount":84},[],{"trials":832,"activeCount":84},[],{"intervention":828,"totalTrials":80,"cells":834},{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":847,"NA":849},{"trials":836,"activeCount":84},[],{"trials":838,"activeCount":84},[],{"trials":840,"activeCount":84},[],{"trials":842,"activeCount":84},[843],{"nctId":815,"briefTitle":816,"status":367,"phases":844,"primaryCompletion":818,"completion":819,"start":820,"enrollment":821,"conditions":845,"interventions":846},[74,75],[823,824,825,826],[804,828],{"trials":848,"activeCount":84},[],{"trials":850,"activeCount":84},[],{"intervention":852,"totalTrials":80,"cells":853},"EMLA cream",{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":858,"PHASE3":860,"PHASE4":871,"NA":873},{"trials":855,"activeCount":84},[],{"trials":857,"activeCount":84},[],{"trials":859,"activeCount":84},[],{"trials":861,"activeCount":84},[862],{"nctId":863,"briefTitle":864,"status":367,"phases":865,"primaryCompletion":866,"completion":866,"start":867,"enrollment":445,"conditions":868,"interventions":870},"NCT00959595","Improvement of Sensibility in the Foot in Diabetic Patients Induced by EMLA-application to the Lower Leg",[75],"2010-01","2008-11",[869],"Diabetes Mellitus",[852,852],{"trials":872,"activeCount":84},[],{"trials":874,"activeCount":84},[],{"intervention":723,"totalTrials":80,"cells":876},{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":883,"PHASE4":889,"NA":891},{"trials":878,"activeCount":84},[],{"trials":880,"activeCount":84},[],{"trials":882,"activeCount":84},[],{"trials":884,"activeCount":84},[885],{"nctId":715,"briefTitle":716,"status":367,"phases":886,"primaryCompletion":402,"completion":402,"start":718,"enrollment":719,"conditions":887,"interventions":888},[75],[721],[723,704,704,724],{"trials":890,"activeCount":84},[],{"trials":892,"activeCount":84},[],{"intervention":724,"totalTrials":80,"cells":894},{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":907,"NA":909},{"trials":896,"activeCount":84},[],{"trials":898,"activeCount":84},[],{"trials":900,"activeCount":84},[],{"trials":902,"activeCount":84},[903],{"nctId":715,"briefTitle":716,"status":367,"phases":904,"primaryCompletion":402,"completion":402,"start":718,"enrollment":719,"conditions":905,"interventions":906},[75],[721],[723,704,704,724],{"trials":908,"activeCount":84},[],{"trials":910,"activeCount":84},[],{"intervention":736,"totalTrials":80,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":919,"PHASE4":925,"NA":927},{"trials":914,"activeCount":84},[],{"trials":916,"activeCount":84},[],{"trials":918,"activeCount":84},[],{"trials":920,"activeCount":84},[921],{"nctId":726,"briefTitle":727,"status":367,"phases":922,"primaryCompletion":729,"completion":730,"start":731,"enrollment":732,"conditions":923,"interventions":924},[75],[734],[736,704],{"trials":926,"activeCount":84},[],{"trials":928,"activeCount":84},[],{"intervention":930,"totalTrials":931,"cells":932},"Rituximab",3,{"EARLY_PHASE1":933,"PHASE1":949,"PHASE2":951,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":934,"activeCount":84},[935],{"nctId":936,"briefTitle":937,"status":938,"phases":939,"primaryCompletion":940,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":945},"NCT00790413","Haploidentical Stem Cell Transplantation in Neuroblastoma","UNKNOWN",[72],"2022-12-31","2005-08",15,[944],"Neuroblastoma",[946,947,948,930],"iodine I 131 metaiodobenzylguanidine","Fludarabine","Thiotepa",{"trials":950,"activeCount":84},[],{"trials":952,"activeCount":84},[953,964],{"nctId":954,"briefTitle":955,"status":367,"phases":956,"primaryCompletion":957,"completion":957,"start":563,"enrollment":958,"conditions":959,"interventions":961},"NCT02460276","A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed\u002FRefractory Mantle Cell Lymphoma",[74],"2019-12-31",50,[960],"Relapsed\u002FRefractory Mantle Cell Lymphoma",[962,963,930],"Lenalidomide","Ibrutinib",{"nctId":965,"briefTitle":966,"status":367,"phases":967,"primaryCompletion":968,"completion":968,"start":676,"enrollment":958,"conditions":969,"interventions":971},"NCT01622439","Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma",[73,74],"2018-03",[970],"Diffuse Large B-cell Lymphoma",[972,930,973,974,975,976],"Valproate","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone",{"trials":978,"activeCount":84},[],{"trials":980,"activeCount":84},[],{"trials":982,"activeCount":84},[],{"intervention":972,"totalTrials":665,"cells":984},{"EARLY_PHASE1":985,"PHASE1":996,"PHASE2":998,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":986,"activeCount":84},[987],{"nctId":988,"briefTitle":989,"status":367,"phases":990,"primaryCompletion":991,"completion":992,"start":495,"enrollment":34,"conditions":993,"interventions":995},"NCT02144623","Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia",[72],"2016-02","2017-02-06",[994],"Chronic Lymphocytic Leukemia",[972],{"trials":997,"activeCount":84},[],{"trials":999,"activeCount":84},[1000],{"nctId":965,"briefTitle":966,"status":367,"phases":1001,"primaryCompletion":968,"completion":968,"start":676,"enrollment":958,"conditions":1002,"interventions":1003},[73,74],[970],[972,930,973,974,975,976],{"trials":1005,"activeCount":84},[],{"trials":1007,"activeCount":84},[],{"trials":1009,"activeCount":84},[],{"intervention":1011,"totalTrials":80,"cells":1012},"Oxaliplatin and fluorouracil.",{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1029,"PHASE4":1031,"NA":1033},{"trials":1014,"activeCount":84},[],{"trials":1016,"activeCount":84},[],{"trials":1018,"activeCount":84},[1019],{"nctId":1020,"briefTitle":1021,"status":367,"phases":1022,"primaryCompletion":1023,"completion":1023,"start":1024,"enrollment":1025,"conditions":1026,"interventions":1028},"NCT02241499","Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.",[74],"2019-05","2014-10",29,[1027],"Adenocarcinoma of the Esophagus or Esophagogastric Junction",[1011],{"trials":1030,"activeCount":84},[],{"trials":1032,"activeCount":84},[],{"trials":1034,"activeCount":84},[],{"intervention":1036,"totalTrials":80,"cells":1037},"Atorvastatin",{"EARLY_PHASE1":1038,"PHASE1":1040,"PHASE2":1042,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1039,"activeCount":84},[],{"trials":1041,"activeCount":84},[],{"trials":1043,"activeCount":84},[1044],{"nctId":1045,"briefTitle":1046,"status":367,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":958,"conditions":1050,"interventions":1052},"NCT00816244","Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer",[74],"2012-03","2009-01",[26,1051],"Postmenopausal",[1036],{"trials":1054,"activeCount":84},[],{"trials":1056,"activeCount":84},[],{"trials":1058,"activeCount":84},[],{"intervention":1060,"totalTrials":80,"cells":1061},"Letrozole",{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1079,"PHASE4":1081,"NA":1083},{"trials":1063,"activeCount":84},[],{"trials":1065,"activeCount":84},[],{"trials":1067,"activeCount":84},[1068],{"nctId":1069,"briefTitle":1070,"status":367,"phases":1071,"primaryCompletion":1072,"completion":1073,"start":1072,"enrollment":1074,"conditions":1075,"interventions":1076},"NCT02958852","A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant\u002FAromatase Inhibitors) in Patients With Advanced Breast Cancer",[74],"2025-01-02","2025-01-15",126,[26],[1060,1077,1078],"Letrozole and atorvastatin","Fulvestrant",{"trials":1080,"activeCount":84},[],{"trials":1082,"activeCount":84},[],{"trials":1084,"activeCount":84},[],{"intervention":1077,"totalTrials":80,"cells":1086},{"EARLY_PHASE1":1087,"PHASE1":1089,"PHASE2":1091,"PHASE3":1097,"PHASE4":1099,"NA":1101},{"trials":1088,"activeCount":84},[],{"trials":1090,"activeCount":84},[],{"trials":1092,"activeCount":84},[1093],{"nctId":1069,"briefTitle":1070,"status":367,"phases":1094,"primaryCompletion":1072,"completion":1073,"start":1072,"enrollment":1074,"conditions":1095,"interventions":1096},[74],[26],[1060,1077,1078],{"trials":1098,"activeCount":84},[],{"trials":1100,"activeCount":84},[],{"trials":1102,"activeCount":84},[],{"intervention":1078,"totalTrials":80,"cells":1104},{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1115,"PHASE4":1117,"NA":1119},{"trials":1106,"activeCount":84},[],{"trials":1108,"activeCount":84},[],{"trials":1110,"activeCount":84},[1111],{"nctId":1069,"briefTitle":1070,"status":367,"phases":1112,"primaryCompletion":1072,"completion":1073,"start":1072,"enrollment":1074,"conditions":1113,"interventions":1114},[74],[26],[1060,1077,1078],{"trials":1116,"activeCount":84},[],{"trials":1118,"activeCount":84},[],{"trials":1120,"activeCount":84},[],{"intervention":1122,"totalTrials":80,"cells":1123},"Diamyd",{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1139,"PHASE4":1141,"NA":1143},{"trials":1125,"activeCount":84},[],{"trials":1127,"activeCount":84},[],{"trials":1129,"activeCount":84},[1130],{"nctId":1131,"briefTitle":1132,"status":367,"phases":1133,"primaryCompletion":469,"completion":469,"start":1134,"enrollment":958,"conditions":1135,"interventions":1138},"NCT01122446","Diabetes Prevention - Immune Tolerance",[74],"2009-04",[1136,1137],"Prediabetes","Type 1 Diabetes",[1122],{"trials":1140,"activeCount":84},[],{"trials":1142,"activeCount":84},[],{"trials":1144,"activeCount":84},[],{"intervention":1146,"totalTrials":80,"cells":1147},"Alum-GAD",{"EARLY_PHASE1":1148,"PHASE1":1150,"PHASE2":1152,"PHASE3":1166,"PHASE4":1168,"NA":1170},{"trials":1149,"activeCount":84},[],{"trials":1151,"activeCount":84},[],{"trials":1153,"activeCount":84},[1154],{"nctId":1155,"briefTitle":1156,"status":584,"phases":1157,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1164},"NCT02387164","Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies",[74],"2019-10-07","2015-03-09",26,[1162,1163],"Diabetes Mellitus, Type 1","Prediabetic State",[1146,1165],"Vitamin D3",{"trials":1167,"activeCount":84},[],{"trials":1169,"activeCount":84},[],{"trials":1171,"activeCount":84},[],{"intervention":1165,"totalTrials":80,"cells":1173},{"EARLY_PHASE1":1174,"PHASE1":1176,"PHASE2":1178,"PHASE3":1184,"PHASE4":1186,"NA":1188},{"trials":1175,"activeCount":84},[],{"trials":1177,"activeCount":84},[],{"trials":1179,"activeCount":84},[1180],{"nctId":1155,"briefTitle":1156,"status":584,"phases":1181,"primaryCompletion":1158,"completion":1158,"start":1159,"enrollment":1160,"conditions":1182,"interventions":1183},[74],[1162,1163],[1146,1165],{"trials":1185,"activeCount":84},[],{"trials":1187,"activeCount":84},[],{"trials":1189,"activeCount":84},[],{"intervention":1191,"totalTrials":80,"cells":1192},"90Y-ibritumomab",{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1194,"activeCount":84},[],{"trials":1196,"activeCount":84},[],{"trials":1198,"activeCount":84},[1199],{"nctId":1200,"briefTitle":1201,"status":367,"phases":1202,"primaryCompletion":370,"completion":370,"start":1203,"enrollment":1204,"conditions":1205,"interventions":1207},"NCT00761384","High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma",[73,74],"2008-04",7,[1206],"B-cell Lymphoma",[1191],{"trials":1209,"activeCount":84},[],{"trials":1211,"activeCount":84},[],{"trials":1213,"activeCount":84},[],{"intervention":1215,"totalTrials":80,"cells":1216},"lenalidomide, bendamustine, rituximab",{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1232,"PHASE4":1234,"NA":1236},{"trials":1218,"activeCount":84},[],{"trials":1220,"activeCount":84},[],{"trials":1222,"activeCount":84},[1223],{"nctId":1224,"briefTitle":1225,"status":367,"phases":1226,"primaryCompletion":390,"completion":390,"start":1227,"enrollment":1228,"conditions":1229,"interventions":1231},"NCT00963534","Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.",[73,74],"2009-09",51,[1230],"Mantle Cell Lymphoma",[1215,1215],{"trials":1233,"activeCount":84},[],{"trials":1235,"activeCount":84},[],{"trials":1237,"activeCount":84},[],{"intervention":1239,"totalTrials":80,"cells":1240},"177Lu-DOTA-TATE",{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1255,"PHASE4":1257,"NA":1259},{"trials":1242,"activeCount":84},[],{"trials":1244,"activeCount":84},[],{"trials":1246,"activeCount":84},[1247],{"nctId":1248,"briefTitle":1249,"status":367,"phases":1250,"primaryCompletion":1251,"completion":1251,"start":1252,"enrollment":240,"conditions":1253,"interventions":1254},"NCT01456078","A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors",[74],"2018-11","2011-10",[138,823],[1239],{"trials":1256,"activeCount":84},[],{"trials":1258,"activeCount":84},[],{"trials":1260,"activeCount":84},[],{"intervention":1262,"totalTrials":80,"cells":1263},"Clofarabine for remission induction",{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1285,"PHASE4":1287,"NA":1289},{"trials":1265,"activeCount":84},[],{"trials":1267,"activeCount":84},[],{"trials":1269,"activeCount":84},[1270],{"nctId":1271,"briefTitle":1272,"status":367,"phases":1273,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1204,"conditions":1276,"interventions":1279},"NCT01025778","Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia",[74],"2012-12","2009-12",[1277,1278],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia",[1262,1280,1281,1282,1283,1284],"Etoposide for remission induction","Cyclophosphamide for remission induction","Clofarabine in conditioning before transplantation","Thiotepa in conditioning before transplantation","Melfalan in conditioning before transplantation",{"trials":1286,"activeCount":84},[],{"trials":1288,"activeCount":84},[],{"trials":1290,"activeCount":84},[],{"intervention":1280,"totalTrials":80,"cells":1292},{"EARLY_PHASE1":1293,"PHASE1":1295,"PHASE2":1297,"PHASE3":1303,"PHASE4":1305,"NA":1307},{"trials":1294,"activeCount":84},[],{"trials":1296,"activeCount":84},[],{"trials":1298,"activeCount":84},[1299],{"nctId":1271,"briefTitle":1272,"status":367,"phases":1300,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1204,"conditions":1301,"interventions":1302},[74],[1277,1278],[1262,1280,1281,1282,1283,1284],{"trials":1304,"activeCount":84},[],{"trials":1306,"activeCount":84},[],{"trials":1308,"activeCount":84},[],{"intervention":1281,"totalTrials":80,"cells":1310},{"EARLY_PHASE1":1311,"PHASE1":1313,"PHASE2":1315,"PHASE3":1321,"PHASE4":1323,"NA":1325},{"trials":1312,"activeCount":84},[],{"trials":1314,"activeCount":84},[],{"trials":1316,"activeCount":84},[1317],{"nctId":1271,"briefTitle":1272,"status":367,"phases":1318,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1204,"conditions":1319,"interventions":1320},[74],[1277,1278],[1262,1280,1281,1282,1283,1284],{"trials":1322,"activeCount":84},[],{"trials":1324,"activeCount":84},[],{"trials":1326,"activeCount":84},[],{"intervention":1282,"totalTrials":80,"cells":1328},{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1339,"PHASE4":1341,"NA":1343},{"trials":1330,"activeCount":84},[],{"trials":1332,"activeCount":84},[],{"trials":1334,"activeCount":84},[1335],{"nctId":1271,"briefTitle":1272,"status":367,"phases":1336,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1204,"conditions":1337,"interventions":1338},[74],[1277,1278],[1262,1280,1281,1282,1283,1284],{"trials":1340,"activeCount":84},[],{"trials":1342,"activeCount":84},[],{"trials":1344,"activeCount":84},[],{"intervention":1283,"totalTrials":80,"cells":1346},{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1357,"PHASE4":1359,"NA":1361},{"trials":1348,"activeCount":84},[],{"trials":1350,"activeCount":84},[],{"trials":1352,"activeCount":84},[1353],{"nctId":1271,"briefTitle":1272,"status":367,"phases":1354,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1204,"conditions":1355,"interventions":1356},[74],[1277,1278],[1262,1280,1281,1282,1283,1284],{"trials":1358,"activeCount":84},[],{"trials":1360,"activeCount":84},[],{"trials":1362,"activeCount":84},[],{"intervention":1284,"totalTrials":80,"cells":1364},{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1375,"PHASE4":1377,"NA":1379},{"trials":1366,"activeCount":84},[],{"trials":1368,"activeCount":84},[],{"trials":1370,"activeCount":84},[1371],{"nctId":1271,"briefTitle":1272,"status":367,"phases":1372,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1204,"conditions":1373,"interventions":1374},[74],[1277,1278],[1262,1280,1281,1282,1283,1284],{"trials":1376,"activeCount":84},[],{"trials":1378,"activeCount":84},[],{"trials":1380,"activeCount":84},[],{"intervention":962,"totalTrials":80,"cells":1382},{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1393,"PHASE4":1395,"NA":1397},{"trials":1384,"activeCount":84},[],{"trials":1386,"activeCount":84},[],{"trials":1388,"activeCount":84},[1389],{"nctId":954,"briefTitle":955,"status":367,"phases":1390,"primaryCompletion":957,"completion":957,"start":563,"enrollment":958,"conditions":1391,"interventions":1392},[74],[960],[962,963,930],{"trials":1394,"activeCount":84},[],{"trials":1396,"activeCount":84},[],{"trials":1398,"activeCount":84},[],{"intervention":963,"totalTrials":80,"cells":1400},{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1411,"PHASE4":1413,"NA":1415},{"trials":1402,"activeCount":84},[],{"trials":1404,"activeCount":84},[],{"trials":1406,"activeCount":84},[1407],{"nctId":954,"briefTitle":955,"status":367,"phases":1408,"primaryCompletion":957,"completion":957,"start":563,"enrollment":958,"conditions":1409,"interventions":1410},[74],[960],[962,963,930],{"trials":1412,"activeCount":84},[],{"trials":1414,"activeCount":84},[],{"trials":1416,"activeCount":84},[],{"intervention":973,"totalTrials":80,"cells":1418},{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1420,"activeCount":84},[],{"trials":1422,"activeCount":84},[],{"trials":1424,"activeCount":84},[1425],{"nctId":965,"briefTitle":966,"status":367,"phases":1426,"primaryCompletion":968,"completion":968,"start":676,"enrollment":958,"conditions":1427,"interventions":1428},[73,74],[970],[972,930,973,974,975,976],{"trials":1430,"activeCount":84},[],{"trials":1432,"activeCount":84},[],{"trials":1434,"activeCount":84},[],{"intervention":974,"totalTrials":80,"cells":1436},{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1438,"activeCount":84},[],{"trials":1440,"activeCount":84},[],{"trials":1442,"activeCount":84},[1443],{"nctId":965,"briefTitle":966,"status":367,"phases":1444,"primaryCompletion":968,"completion":968,"start":676,"enrollment":958,"conditions":1445,"interventions":1446},[73,74],[970],[972,930,973,974,975,976],{"trials":1448,"activeCount":84},[],{"trials":1450,"activeCount":84},[],{"trials":1452,"activeCount":84},[],{"intervention":975,"totalTrials":80,"cells":1454},{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1465,"PHASE4":1467,"NA":1469},{"trials":1456,"activeCount":84},[],{"trials":1458,"activeCount":84},[],{"trials":1460,"activeCount":84},[1461],{"nctId":965,"briefTitle":966,"status":367,"phases":1462,"primaryCompletion":968,"completion":968,"start":676,"enrollment":958,"conditions":1463,"interventions":1464},[73,74],[970],[972,930,973,974,975,976],{"trials":1466,"activeCount":84},[],{"trials":1468,"activeCount":84},[],{"trials":1470,"activeCount":84},[],{"intervention":976,"totalTrials":80,"cells":1472},{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1474,"activeCount":84},[],{"trials":1476,"activeCount":84},[],{"trials":1478,"activeCount":84},[1479],{"nctId":965,"briefTitle":966,"status":367,"phases":1480,"primaryCompletion":968,"completion":968,"start":676,"enrollment":958,"conditions":1481,"interventions":1482},[73,74],[970],[972,930,973,974,975,976],{"trials":1484,"activeCount":84},[],{"trials":1486,"activeCount":84},[],{"trials":1488,"activeCount":84},[],{"intervention":682,"totalTrials":80,"cells":1490},{"EARLY_PHASE1":1491,"PHASE1":1493,"PHASE2":1499,"PHASE3":1501,"PHASE4":1503,"NA":1505},{"trials":1492,"activeCount":84},[],{"trials":1494,"activeCount":84},[1495],{"nctId":672,"briefTitle":673,"status":367,"phases":1496,"primaryCompletion":675,"completion":675,"start":676,"enrollment":677,"conditions":1497,"interventions":1498},[73],[679],[681,682,683],{"trials":1500,"activeCount":84},[],{"trials":1502,"activeCount":84},[],{"trials":1504,"activeCount":84},[],{"trials":1506,"activeCount":84},[],{"intervention":683,"totalTrials":80,"cells":1508},{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1510,"activeCount":84},[],{"trials":1512,"activeCount":84},[1513],{"nctId":672,"briefTitle":673,"status":367,"phases":1514,"primaryCompletion":675,"completion":675,"start":676,"enrollment":677,"conditions":1515,"interventions":1516},[73],[679],[681,682,683],{"trials":1518,"activeCount":84},[],{"trials":1520,"activeCount":84},[],{"trials":1522,"activeCount":84},[],{"trials":1524,"activeCount":84},[],{"intervention":946,"totalTrials":80,"cells":1526},{"EARLY_PHASE1":1527,"PHASE1":1533,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1541},{"trials":1528,"activeCount":84},[1529],{"nctId":936,"briefTitle":937,"status":938,"phases":1530,"primaryCompletion":940,"completion":940,"start":941,"enrollment":942,"conditions":1531,"interventions":1532},[72],[944],[946,947,948,930],{"trials":1534,"activeCount":84},[],{"trials":1536,"activeCount":84},[],{"trials":1538,"activeCount":84},[],{"trials":1540,"activeCount":84},[],{"trials":1542,"activeCount":84},[],{"intervention":947,"totalTrials":80,"cells":1544},{"EARLY_PHASE1":1545,"PHASE1":1551,"PHASE2":1553,"PHASE3":1555,"PHASE4":1557,"NA":1559},{"trials":1546,"activeCount":84},[1547],{"nctId":936,"briefTitle":937,"status":938,"phases":1548,"primaryCompletion":940,"completion":940,"start":941,"enrollment":942,"conditions":1549,"interventions":1550},[72],[944],[946,947,948,930],{"trials":1552,"activeCount":84},[],{"trials":1554,"activeCount":84},[],{"trials":1556,"activeCount":84},[],{"trials":1558,"activeCount":84},[],{"trials":1560,"activeCount":84},[],{"intervention":948,"totalTrials":80,"cells":1562},{"EARLY_PHASE1":1563,"PHASE1":1569,"PHASE2":1571,"PHASE3":1573,"PHASE4":1575,"NA":1577},{"trials":1564,"activeCount":84},[1565],{"nctId":936,"briefTitle":937,"status":938,"phases":1566,"primaryCompletion":940,"completion":940,"start":941,"enrollment":942,"conditions":1567,"interventions":1568},[72],[944],[946,947,948,930],{"trials":1570,"activeCount":84},[],{"trials":1572,"activeCount":84},[],{"trials":1574,"activeCount":84},[],{"trials":1576,"activeCount":84},[],{"trials":1578,"activeCount":84},[],{"intervention":396,"totalTrials":34,"cells":1580},{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1587,"PHASE4":1589,"NA":1611},{"trials":1582,"activeCount":84},[],{"trials":1584,"activeCount":84},[],{"trials":1586,"activeCount":84},[],{"trials":1588,"activeCount":84},[],{"trials":1590,"activeCount":84},[1591,1597,1607],{"nctId":1592,"briefTitle":1593,"status":367,"phases":1594,"primaryCompletion":369,"completion":369,"start":563,"enrollment":371,"conditions":1595,"interventions":1596},"NCT02256189","Sitagliptin and Glucagon Counterregulation",[76],[21],[396],{"nctId":1598,"briefTitle":1599,"status":367,"phases":1600,"primaryCompletion":1601,"completion":1602,"start":1603,"enrollment":1604,"conditions":1605,"interventions":1606},"NCT00885638","Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion",[76],"2011-05","2012-09","2009-08",12,[19,21],[396],{"nctId":387,"briefTitle":388,"status":367,"phases":1608,"primaryCompletion":369,"completion":390,"start":391,"enrollment":392,"conditions":1609,"interventions":1610},[76],[21],[395,352,396],{"trials":1612,"activeCount":84},[1613],{"nctId":1614,"briefTitle":1615,"status":367,"phases":1616,"primaryCompletion":587,"completion":587,"start":1617,"enrollment":1604,"conditions":1618,"interventions":1619},"NCT01901861","Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes",[77],"2013-07",[21],[396],{"intervention":1621,"totalTrials":665,"cells":1622},"Effects of Oat and Oat Components on Cardiometabolic risk variables",{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1627,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1624,"activeCount":84},[],{"trials":1626,"activeCount":84},[],{"trials":1628,"activeCount":84},[],{"trials":1630,"activeCount":84},[],{"trials":1632,"activeCount":84},[],{"trials":1634,"activeCount":84},[1635,1645],{"nctId":1636,"briefTitle":1637,"status":367,"phases":1638,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":1641,"conditions":1642,"interventions":1644},"NCT04542265","Health Effects of Oat and Oat Bioactive in Human",[77],"2020-12-18","2020-08-28",20,[1643],"Postprandial Glucose Regulation",[1621],{"nctId":1646,"briefTitle":1647,"status":367,"phases":1648,"primaryCompletion":1649,"completion":1650,"start":1651,"enrollment":1641,"conditions":1652,"interventions":1653},"NCT05139355","Health Effects of Oat and Oat Polar Lipids in Human",[77],"2022-02-26","2022-03-15","2021-11-16",[1643],[1621],{"intervention":1655,"totalTrials":80,"cells":1656},"Oat Beverage 1",{"EARLY_PHASE1":1657,"PHASE1":1659,"PHASE2":1661,"PHASE3":1663,"PHASE4":1665,"NA":1667},{"trials":1658,"activeCount":84},[],{"trials":1660,"activeCount":84},[],{"trials":1662,"activeCount":84},[],{"trials":1664,"activeCount":84},[],{"trials":1666,"activeCount":84},[],{"trials":1668,"activeCount":84},[1669],{"nctId":1670,"briefTitle":1671,"status":367,"phases":1672,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":392,"conditions":1676,"interventions":1677},"NCT03830736","Health Effects of Oats and Oat Bioactive in Human",[77],"2019-05-30","2019-12-30","2019-02-18",[1643],[1655,1678,1679,1680,1681],"Oat Beverage 2","Oat Beverage 3","Oat Beverage 4","Control product",{"intervention":1678,"totalTrials":80,"cells":1683},{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1688,"PHASE3":1690,"PHASE4":1692,"NA":1694},{"trials":1685,"activeCount":84},[],{"trials":1687,"activeCount":84},[],{"trials":1689,"activeCount":84},[],{"trials":1691,"activeCount":84},[],{"trials":1693,"activeCount":84},[],{"trials":1695,"activeCount":84},[1696],{"nctId":1670,"briefTitle":1671,"status":367,"phases":1697,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":392,"conditions":1698,"interventions":1699},[77],[1643],[1655,1678,1679,1680,1681],{"intervention":1679,"totalTrials":80,"cells":1701},{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1706,"PHASE3":1708,"PHASE4":1710,"NA":1712},{"trials":1703,"activeCount":84},[],{"trials":1705,"activeCount":84},[],{"trials":1707,"activeCount":84},[],{"trials":1709,"activeCount":84},[],{"trials":1711,"activeCount":84},[],{"trials":1713,"activeCount":84},[1714],{"nctId":1670,"briefTitle":1671,"status":367,"phases":1715,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":392,"conditions":1716,"interventions":1717},[77],[1643],[1655,1678,1679,1680,1681],{"intervention":1680,"totalTrials":80,"cells":1719},{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1721,"activeCount":84},[],{"trials":1723,"activeCount":84},[],{"trials":1725,"activeCount":84},[],{"trials":1727,"activeCount":84},[],{"trials":1729,"activeCount":84},[],{"trials":1731,"activeCount":84},[1732],{"nctId":1670,"briefTitle":1671,"status":367,"phases":1733,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":392,"conditions":1734,"interventions":1735},[77],[1643],[1655,1678,1679,1680,1681],{"intervention":1681,"totalTrials":80,"cells":1737},{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1739,"activeCount":84},[],{"trials":1741,"activeCount":84},[],{"trials":1743,"activeCount":84},[],{"trials":1745,"activeCount":84},[],{"trials":1747,"activeCount":84},[],{"trials":1749,"activeCount":84},[1750],{"nctId":1670,"briefTitle":1671,"status":367,"phases":1751,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":392,"conditions":1752,"interventions":1753},[77],[1643],[1655,1678,1679,1680,1681],{"intervention":1755,"totalTrials":80,"cells":1756},"Germline genetic testing of BRCA1 and BRCA2",{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1761,"PHASE3":1763,"PHASE4":1765,"NA":1767},{"trials":1758,"activeCount":84},[],{"trials":1760,"activeCount":84},[],{"trials":1762,"activeCount":84},[],{"trials":1764,"activeCount":84},[],{"trials":1766,"activeCount":84},[],{"trials":1768,"activeCount":84},[1769],{"nctId":1770,"briefTitle":1771,"status":367,"phases":1772,"primaryCompletion":968,"completion":968,"start":1773,"enrollment":1774,"conditions":1775,"interventions":1777},"NCT02557776","Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer",[77],"2015-02",542,[1776],"Hereditary Breast Cancer",[1755],{"intervention":1779,"totalTrials":80,"cells":1780},"iloprost",{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1787,"PHASE4":1789,"NA":1791},{"trials":1782,"activeCount":84},[],{"trials":1784,"activeCount":84},[],{"trials":1786,"activeCount":84},[],{"trials":1788,"activeCount":84},[],{"trials":1790,"activeCount":84},[],{"trials":1792,"activeCount":84},[1793],{"nctId":1794,"briefTitle":1795,"status":491,"phases":1796,"completion":1797,"start":1798,"enrollment":1799,"conditions":1800,"interventions":1803},"NCT00216931","Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost",[77],"2008-10","2006-05",40,[1801,1802],"Persistent Pulmonary Hypertension","Respiratory Distress Syndrome",[1779],{"intervention":1805,"totalTrials":80,"cells":1806},"carbon-dioxide insufflation",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1811,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1808,"activeCount":84},[],{"trials":1810,"activeCount":84},[],{"trials":1812,"activeCount":84},[],{"trials":1814,"activeCount":84},[],{"trials":1816,"activeCount":84},[],{"trials":1818,"activeCount":84},[1819],{"nctId":1820,"briefTitle":1821,"status":367,"phases":1822,"primaryCompletion":729,"completion":729,"start":1823,"enrollment":1641,"conditions":1824,"interventions":1826},"NCT00934596","CO2 Versus Lund De-airing Technique in Heart Surgery",[77],"2009-06",[1825],"Aortic Valve Disorder",[1805],{"intervention":1828,"totalTrials":80,"cells":1829},"Prevenar",{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1831,"activeCount":84},[],{"trials":1833,"activeCount":84},[],{"trials":1835,"activeCount":84},[],{"trials":1837,"activeCount":84},[],{"trials":1839,"activeCount":84},[],{"trials":1841,"activeCount":84},[1842],{"nctId":1843,"briefTitle":1844,"status":367,"phases":1845,"primaryCompletion":1823,"completion":1846,"start":1847,"enrollment":1848,"conditions":1849,"interventions":1851},"NCT01263210","Pneumococcal Vaccination of Otitis-prone Children",[77],"2010-06","2003-03",109,[1850],"Recurrent Acute Otitis Media",[1828],{"intervention":1853,"totalTrials":80,"cells":1854},"Follitropin alpha",{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1865},{"trials":1856,"activeCount":84},[],{"trials":1858,"activeCount":84},[],{"trials":1860,"activeCount":84},[],{"trials":1862,"activeCount":84},[],{"trials":1864,"activeCount":84},[],{"trials":1866,"activeCount":84},[1867],{"nctId":1868,"briefTitle":1869,"status":367,"phases":1870,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":1875,"interventions":1877},"NCT03737253","Hormone Evaluation in Artificial Reproductive Technology",[77],"2021-12-31","2024-10-02","2016-09",810,[1876],"Female Infertility",[1853,1878],"Menotropin",{"intervention":1878,"totalTrials":80,"cells":1880},{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1887,"PHASE4":1889,"NA":1891},{"trials":1882,"activeCount":84},[],{"trials":1884,"activeCount":84},[],{"trials":1886,"activeCount":84},[],{"trials":1888,"activeCount":84},[],{"trials":1890,"activeCount":84},[],{"trials":1892,"activeCount":84},[1893],{"nctId":1868,"briefTitle":1869,"status":367,"phases":1894,"primaryCompletion":1871,"completion":1872,"start":1873,"enrollment":1874,"conditions":1895,"interventions":1896},[77],[1876],[1853,1878],{"intervention":1898,"totalTrials":80,"cells":1899},"Acupuncture, acupressure",{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1906,"PHASE4":1908,"NA":1910},{"trials":1901,"activeCount":84},[],{"trials":1903,"activeCount":84},[],{"trials":1905,"activeCount":84},[],{"trials":1907,"activeCount":84},[],{"trials":1909,"activeCount":84},[],{"trials":1911,"activeCount":84},[1912],{"nctId":1913,"briefTitle":1914,"status":938,"phases":1915,"primaryCompletion":1916,"completion":1917,"start":1918,"enrollment":1919,"conditions":1920,"interventions":1922},"NCT03292068","Children Recovering From Tonsil Surgery",[77],"2022-09-01","2022-12-01","2019-01-01",576,[1921],"Tonsillitis",[1898],{"intervention":1924,"totalTrials":80,"cells":1925},"Racemic ketamine",{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1932,"PHASE4":1934,"NA":1936},{"trials":1927,"activeCount":84},[],{"trials":1929,"activeCount":84},[],{"trials":1931,"activeCount":84},[],{"trials":1933,"activeCount":84},[],{"trials":1935,"activeCount":84},[],{"trials":1937,"activeCount":84},[1938],{"nctId":1939,"briefTitle":1940,"status":367,"phases":1941,"primaryCompletion":1942,"completion":1942,"start":1601,"enrollment":10,"conditions":1943,"interventions":1945},"NCT01506921","Racemic Ketamine Versus S-ketamine With Arterial Spin Labeling (ASL)-MRI in Healthy Volunteers",[77],"2012-02",[19,1944],"Abnormal Vascular Flow",[1924,1946],"S-ketamine",{"intervention":1946,"totalTrials":80,"cells":1948},{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1955,"PHASE4":1957,"NA":1959},{"trials":1950,"activeCount":84},[],{"trials":1952,"activeCount":84},[],{"trials":1954,"activeCount":84},[],{"trials":1956,"activeCount":84},[],{"trials":1958,"activeCount":84},[],{"trials":1960,"activeCount":84},[1961],{"nctId":1939,"briefTitle":1940,"status":367,"phases":1962,"primaryCompletion":1942,"completion":1942,"start":1601,"enrollment":10,"conditions":1963,"interventions":1964},[77],[19,1944],[1924,1946],{"intervention":1966,"totalTrials":80,"cells":1967},"Treatment with recombinant coagulation factor",{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1974,"PHASE4":1976,"NA":1978},{"trials":1969,"activeCount":84},[],{"trials":1971,"activeCount":84},[],{"trials":1973,"activeCount":84},[],{"trials":1975,"activeCount":84},[],{"trials":1977,"activeCount":84},[],{"trials":1979,"activeCount":84},[1980],{"nctId":1981,"briefTitle":1982,"status":367,"phases":1983,"primaryCompletion":1984,"completion":1984,"start":1985,"enrollment":1986,"conditions":1987,"interventions":1988},"NCT03313531","Evaluation of a Standardized Protocol for Thrombin Generation Assay",[],"2019-01-28","2017-04-15",9,[471],[1966],{"intervention":1990,"totalTrials":80,"cells":1991},"Degarelix 120 MG [Firmagon]",{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":1996,"PHASE3":1998,"PHASE4":2000,"NA":2002},{"trials":1993,"activeCount":84},[],{"trials":1995,"activeCount":84},[],{"trials":1997,"activeCount":84},[],{"trials":1999,"activeCount":84},[],{"trials":2001,"activeCount":84},[],{"trials":2003,"activeCount":84},[2004],{"nctId":2005,"briefTitle":2006,"status":367,"phases":2007,"primaryCompletion":94,"completion":957,"start":2008,"enrollment":300,"conditions":2009,"interventions":2011},"NCT04134130","The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer",[77],"2019-09-16",[2010],"Prostate Cancer Recurrent",[1990,2012,2013],"Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector","Testosterone Undecanoate",{"intervention":2012,"totalTrials":80,"cells":2015},{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2020,"PHASE3":2022,"PHASE4":2024,"NA":2026},{"trials":2017,"activeCount":84},[],{"trials":2019,"activeCount":84},[],{"trials":2021,"activeCount":84},[],{"trials":2023,"activeCount":84},[],{"trials":2025,"activeCount":84},[],{"trials":2027,"activeCount":84},[2028],{"nctId":2005,"briefTitle":2006,"status":367,"phases":2029,"primaryCompletion":94,"completion":957,"start":2008,"enrollment":300,"conditions":2030,"interventions":2031},[77],[2010],[1990,2012,2013],{"intervention":2013,"totalTrials":80,"cells":2033},{"EARLY_PHASE1":2034,"PHASE1":2036,"PHASE2":2038,"PHASE3":2040,"PHASE4":2042,"NA":2044},{"trials":2035,"activeCount":84},[],{"trials":2037,"activeCount":84},[],{"trials":2039,"activeCount":84},[],{"trials":2041,"activeCount":84},[],{"trials":2043,"activeCount":84},[],{"trials":2045,"activeCount":84},[2046],{"nctId":2005,"briefTitle":2006,"status":367,"phases":2047,"primaryCompletion":94,"completion":957,"start":2008,"enrollment":300,"conditions":2048,"interventions":2049},[77],[2010],[1990,2012,2013],{"intervention":2051,"totalTrials":80,"cells":2052},"GnRH antagonist",{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2057,"PHASE3":2059,"PHASE4":2061,"NA":2063},{"trials":2054,"activeCount":84},[],{"trials":2056,"activeCount":84},[],{"trials":2058,"activeCount":84},[],{"trials":2060,"activeCount":84},[],{"trials":2062,"activeCount":84},[],{"trials":2064,"activeCount":84},[2065],{"nctId":2066,"briefTitle":2067,"status":367,"phases":2068,"primaryCompletion":2069,"completion":2069,"start":2070,"enrollment":2071,"conditions":2072,"interventions":2074},"NCT03541395","Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males",[77],"2015-06","2015-03",30,[2073],"Hypogonadism, Male",[2051],{"intervention":2076,"totalTrials":80,"cells":2077},"Gemcitabine",{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2084,"PHASE4":2086,"NA":2088},{"trials":2079,"activeCount":84},[],{"trials":2081,"activeCount":84},[],{"trials":2083,"activeCount":84},[],{"trials":2085,"activeCount":84},[],{"trials":2087,"activeCount":84},[],{"trials":2089,"activeCount":84},[2090],{"nctId":2091,"briefTitle":2092,"status":367,"phases":2093,"primaryCompletion":2094,"completion":2094,"start":2095,"enrollment":2096,"conditions":2097,"interventions":2101},"NCT03724994","Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer",[],"2024-12-31","2018-10-30",201,[2098,2099,2100],"Periampullary Adenocarcinoma","Periampullary Cancer","Pancreatic Cancer",[2076],{"intervention":2103,"totalTrials":80,"cells":2104},"Factor VIII replacement",{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2109,"PHASE3":2111,"PHASE4":2113,"NA":2115},{"trials":2106,"activeCount":84},[],{"trials":2108,"activeCount":84},[],{"trials":2110,"activeCount":84},[],{"trials":2112,"activeCount":84},[],{"trials":2114,"activeCount":84},[],{"trials":2116,"activeCount":84},[2117],{"nctId":2118,"briefTitle":2119,"status":491,"phases":2120,"primaryCompletion":2121,"completion":2121,"start":2122,"enrollment":84,"conditions":2123,"interventions":2125},"NCT02996942","Key Aspects of Medical Practice in Patients With Haemophilia A",[],"2017-12","2012-07",[2124],"Joint Disease",[2103]]